The NCCN Guidelines for Colorectal Cancer (CRC) Screening outline various screening modalities as well as recommended screening strategies for individuals at average or increased-risk of developing sporadic CRC. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine relevant data, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize 2018 updates to the NCCN Guidelines, with a primary focus on modalities used to screen individuals at average-risk for CRC.

暂无摘要。

The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.

暂无摘要。

The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test (FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed.

暂无摘要。

Decisions regarding colorectal cancer screening will continue to depend on local resources, which in some jurisdictions includes programmatic screening and individual patient preferences. I encourage gastroenterologists to participate in programmatic screening and assist in developing the colonoscopy quality assurance and improvement programs. Our involvement would ensure that we remain leaders in this area and that our expertise in quality in endoscopy is recognized. Finally, participation in programmatic screening should benefit endoscopic services by increasing resources to support higher colonoscopy volumes, shorter wait lists and continuing quality assurance.

In 2002-2003, the Italian Association for Neuroimmunology (AINI) ran a program for procedure and method standardization in neuroimmunology. The main purposes of the program were: a) to improve the overall quality of analytical performance and, simultaneously, to reduce costs by resource optimization; b) to establish the bases for clinical guidelines in neurology; c) to promote the formation of laboratory networks and of joint research projects; d) to facilitate the procedures for certification required by governmental/non-governmental agencies. This report summarizes the consensus recommendations of a panel of AINI neuroimmunologists/biochemists involved in the field of cerebrospinal fluid examination. The collection process for said recommendations was guided by \"impact-factored\" literature and the knowledge of the experts involved. Communication was by email and face-to-face at two dedicated AINI workshops.

暂无摘要。

Streptomyces lividans was transformed with a plasmid containing the structural gene that specifies human interleukin 2. The expression of interleukin 2 in this plasmid is controlled by both the consensus promoter and a consensus ribosome binding site characteristic of Escherichia coli. We have detected production of active human interleukin 2 in liquid cultures of the transformed Streptomyces by both, biological assay and immuno-blotting analysis.